Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development.
OBJECTIVE: To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors.
METHODS: This was a case-control study in patients with obesity undergoing bariatric surgery at a University Hospital between January 2020 and December 2021. Participants were distributed in three groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction-associated steatohepatitis (n = 32). Hepatic and serum FAs levels were determined by GC-MS. The nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by RT-qPCR.
RESULTS: The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared to those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD being significantly different between the three groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD.
CONCLUSION: Alterations in hepatic FA levels in MASLD patients were due to an enhancement of the de novo lipogenesis in the liver.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - (2024) vom: 13. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Núñez-Sánchez, María Ángeles [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Fatty acids |
|---|
| Anmerkungen: |
Date Revised 13.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1210/clinem/dgae028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36708418X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36708418X | ||
| 003 | DE-627 | ||
| 005 | 20240114235110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgae028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1259.xml |
| 035 | |a (DE-627)NLM36708418X | ||
| 035 | |a (NLM)38217869 | ||
| 035 | |a (PII)dgae028 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Núñez-Sánchez, María Ángeles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 13.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a CONTEXT: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the intracellular lipid accumulation in hepatocytes. Excess caloric intake and high-fat diets are considered to significantly contribute to MASLD development | ||
| 520 | |a OBJECTIVE: To evaluate the hepatic and serum fatty acid (FA) composition in patients with different stages of MASLD, and their relationship with FA dietary intake and MASLD-related risk factors | ||
| 520 | |a METHODS: This was a case-control study in patients with obesity undergoing bariatric surgery at a University Hospital between January 2020 and December 2021. Participants were distributed in three groups: no MASLD (n = 26), steatotic liver disease (n = 33), and metabolic dysfunction-associated steatohepatitis (n = 32). Hepatic and serum FAs levels were determined by GC-MS. The nutritional status was evaluated using validated food frequency questionnaires. The hepatic expression of genes involved in FA metabolism was analyzed by RT-qPCR | ||
| 520 | |a RESULTS: The hepatic, but not serum, FA profiles were significantly altered in patients with MASLD compared to those without MASLD. No differences were observed in FA intake between the groups. Levels of C16:0, C18:1, and the C18:1/C18:0 ratio were higher, while C18:0 levels and C18:0/C16:0 ratio were lower in patients with MASLD being significantly different between the three groups. Hepatic FA levels and ratios correlated with histopathological diagnosis and other MASLD-related parameters. The expression of genes involved in the FA metabolism was upregulated in patients with MASLD | ||
| 520 | |a CONCLUSION: Alterations in hepatic FA levels in MASLD patients were due to an enhancement of the de novo lipogenesis in the liver | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fatty acids | |
| 650 | 4 | |a lipidomics | |
| 650 | 4 | |a liver | |
| 650 | 4 | |a metabolic dysfunction-associated steatotic liver disease | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a steatohepatitis | |
| 700 | 1 | |a Martinez-Sanchez, María Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Montoro, José Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Balaguer-Román, Andrés |e verfasserin |4 aut | |
| 700 | 1 | |a Murcia-García, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Ruiz, Virginia Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer-Gómez, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Cáceres, Carlos Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Sledzinski, Tomasz |e verfasserin |4 aut | |
| 700 | 1 | |a Frutos, María Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Morante, Juan José |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-García, José Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Queipo-Ortuño, María Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Alcaraz, Antonio José |e verfasserin |4 aut | |
| 700 | 1 | |a Mika, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Molina, Bruno |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g (2024) vom: 13. Jan. |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:13 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgae028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 13 |c 01 | ||